Athena Athena

X
[{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Myovant Sciences","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"$40.0 million","newsHeadline":"Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"HUNGARY","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Mycenax Biotech","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"$3.0 million","newsHeadline":"Richter and Mycenax Entered into an Asset Purchase Agreement of Biosimilar Tocilizumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"HUNGARY","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$263.5 million","upfrontCash":"Undisclosed","newsHeadline":"Richter Announces the Acquisition of Janssen\u2019s Evra\u00ae Transdermal Contraceptive Patch Assets","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"HUNGARY","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Richter and Hikma Sign Exclusive Commercialisation and License Agreement for Denosumab in the US, a Proposed Biosimilar Referencing Prolia\u00ae and Xgeva\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"HUNGARY","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"HUNGARY","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Sumitomo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO\u00ae for Treatment of Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"HUNGARY","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Gedeon Richter

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

            Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ryeqo

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sumitomo

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration is based on results of preclinical research carried by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years, including globally launched products such as cariprazine (VRAYLAR/REAGILA).

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            According to the agreement, Richter is responsible for the development of the denosumab, Products (to conduct both Phase 1 and Phase 3 global clinical studies) and will supply finished commercial Products for the US market.

            Lead Product(s): Denosumab

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Evra is a transdermal contraceptive patch assets. The deal is complemented by a transitional business license agreement and series of other related agreements to run the business without interruption during the period required to transfer marketing authorizations to Richter.

            Lead Product(s): Norelgestromin,Ethinyl Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Evra

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Johnson & Johnson Innovative Medicine

            Deal Size: $263.5 million Upfront Cash: Undisclosed

            Deal Type: Acquisition December 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Richter receives worldwide rights to develop, manufacture and commercialise the biosimilar tocilizumab for the treatment of rheumatoid arthritis.

            Lead Product(s): Tocilizumab

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Recipient: Mycenax Biotech

            Deal Size: $19.5 million Upfront Cash: $3.0 million

            Deal Type: Agreement April 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Gedeon Richter will commercialize relugolix combination tablet for uterine fibroids and endometriosis in Europe, Russia, Latin America, Australia, and New Zealand.

            Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Myovant Sciences

            Deal Size: $80.0 million Upfront Cash: $40.0 million

            Deal Type: Licensing Agreement March 31, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY